P1.078. Long-Term Follow-Up of Tislelizumab Combined With Chemotherapy or Radiotherapy as Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma (TINES)

Clicks: 1
ID: 325690
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #97 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Esophageal squamous cell carcinoma (ESCC) is a prevalent and aggressive malignancy with limited treatment options. Neoadjuvant therapy has shown promise in improving surgical outcomes and overall survival. This study focuses on long-term follow-up results of tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant treatment for resectable ESCC. Methods Patients with resectable ESCC (T2-4aNanyM0) were randomized into two arms for neoadjuvant therapy. Arm A received tislelizumab (200 mg on day 1), paclitaxel (150 mg/m2 on day 1), and cisplatin (75 mg/m2 on day 1) once every three weeks for three cycles; arm B received radiotherapy with 41.4 Gy in 23 fractions combined with tislelizumab for three cycles. Surgery was planned within four to six weeks post-neoadjuvant therapy. The TINES study enrolled 44 patients between October 2022 and December 2024. The median age was 66 years (37 to 75 years). Most patients were at stage III (75%), cT3 (65.91%), and cN2 (47.73%). Results Among the patients who underwent surgery, the pCR rate was higher in the radiotherapy group compared to the chemotherapy group [60% vs. 31.58%, respectively]. The overall pCR rate was observed to be 41.38%, while the R0 resection rate stood at an impressive figure of 86.21%. The median follow-up time was 23 months (13 months to 40 months). During this period, the median disease-free survival time was 18 months (4 months to 36 months). Although initial observations showed higher postoperative pathological efficacy in the radiotherapy group, further follow-up revealed instances of disease recurrence between 4-7 months post-treatment in this cohort. Specifically, there were 4 cases from radiotherapy group (arm B) with clinical stages ranging from II-IIIB that experienced recurrence, raising questions about optimal selection criteria and management protocols for patients undergoing immuno-radiation therapy regimens. Survival follow-up remains ongoing. Conclusion Combining tislelizumab with either chemotherapy or radiotherapy shows promising efficacy as neoadjuvant treatments for resectable ESCC, particularly highlighting enhanced pCR rates in radiation arm. However, these findings need to be further validated to identify the most appropriate patient population to receive immunotherapy combined with radiotherapy and to optimize treatment regimens to improve long-term survival.
Reference Key
openalex_W7203914345 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yong Zhang, Shaomin Che, Nanzheng Chen, Xinju Li, Tuotuo Gong, Junke Fu, Chenao Yu, Tianren Wang, Runjia Liang, Haozhen Xu, Aoran Liu, Jiangtao You, Xiaohai Cui, AL-AMEERWAILHUSSEIN AHMED
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.226
URL
https://doi.org/10.1093/dote/doag077.226
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.